Strategic Timing of AntiRetroviral Treatment (START) A Multicenter Study of the International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)
Management Using the Latest Technologies in Resource-Limited Settings to Optimize Combination Therapy After Viral Failure (MULTI- OCTAVE)
Phase III Clinical Trial of Ultra-Short-Course Rifapentine/Isoniazid for the Prevention of Active Tuberculosis in HIV-Infected Individuals with Latent Tuberculosis Infection